Redmile Group’s Immunogen Inc IMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-16,423,922
| Closed | -$487M | – | 84 |
|
|
2023
Q4 | $487M | Sell |
16,423,922
-1,079,495
| -6% | -$21.5M | 17.42% | 1 |
|
|
2023
Q3 | $278M | Sell |
17,503,417
-227,000
| -1% | -$3.78M | 13.22% | 1 |
|
|
2023
Q2 | $335M | Buy |
17,730,417
+9,684,200
| +120% | +$114M | 12.84% | 1 |
|
|
2023
Q1 | $30.9M | Sell |
8,046,217
-486,600
| -6% | -$2.07M | 1.34% | 28 |
|
|
2022
Q4 | $42.3M | Sell |
8,532,817
-15,328
| -0.2% | -$83.1K | 1.73% | 20 |
|
|
2022
Q3 | $40.9M | Sell |
8,548,145
-592,900
| -6% | -$3.13M | 1.58% | 20 |
|
|
2022
Q2 | $41.1M | Sell |
9,141,045
-76,900
| -0.8% | -$334K | 1.57% | 19 |
|
|
2022
Q1 | $43.9M | Buy |
9,217,945
+959,600
| +12% | +$5.31M | 1.37% | 19 |
|
|
2021
Q4 | $61.3M | Hold |
8,258,345
| – | – | 1.39% | 19 |
|
|
2021
Q3 | $46.8M | Sell |
8,258,345
-622,600
| -7% | -$3.6M | 0.82% | 41 |
|
|
2021
Q2 | $58.5M | Sell |
8,880,945
-807,121
| -8% | -$5.63M | 0.87% | 36 |
|
|
2021
Q1 | $78.5M | Sell |
9,688,066
-840,113
| -8% | -$6.86M | 1.11% | 33 |
|
|
2020
Q4 | $67.9M | Buy |
10,528,179
+50,300
| +0.5% | +$293K | 0.82% | 39 |
|
|
2020
Q3 | $37.7M | Sell |
10,477,879
-1,529,100
| -13% | -$6.17M | 0.69% | 42 |
|
|
2020
Q2 | $55.2M | Sell |
12,006,979
-4,726,900
| -28% | -$20.1M | 1.02% | 32 |
|
|
2020
Q1 | $57.1M | Buy |
16,733,879
+2,093,919
| +14% | +$9.15M | 1.6% | 19 |
|
|
2019
Q4 | $74.7M | Buy |
14,639,960
+23,400
| +0.2% | +$79.4K | 1.79% | 19 |
|
|
2019
Q3 | $35.4M | Buy |
14,616,560
+661,766
| +5% | +$1.76M | 1.18% | 26 |
|
|
2019
Q2 | $30.3M | Buy |
13,954,794
+891,027
| +7% | +$2.11M | 0.86% | 37 |
|
|
2019
Q1 | $35.4M | Buy |
13,063,767
+2,179,160
| +20% | +$9.44M | 1.04% | 32 |
|
|
2018
Q4 | $52.2M | Sell |
10,884,607
-1,424,428
| -12% | -$8.64M | 2.1% | 15 |
|
|
2018
Q3 | $117M | Sell |
12,309,035
-6,907
| -0.1% | -$66.4K | 3.59% | 6 |
|
|
2018
Q2 | $120M | Buy |
12,315,942
+2,613,460
| +27% | +$27.6M | 4.07% | 4 |
|
|
2018
Q1 | $102M | Sell |
9,702,482
-1,204,480
| -11% | -$11.9M | 3.94% | 4 |
|
|
2017
Q4 | $69.9M | Buy |
10,906,962
+2,845,465
| +35% | +$17.5M | 3.04% | 9 |
|
|
2017
Q3 | $61.7M | Buy |
8,061,497
+2,848,761
| +55% | +$18.9M | 3.04% | 9 |
|
|
2017
Q2 | $37.1M | Buy |
5,212,736
+1,228,002
| +31% | +$5.62M | 2.26% | 13 |
|
|
2017
Q1 | $15.4M | Buy |
+3,984,734
| New | +$11.6M | 1% | 39 |
|
Other funds holding IMGN
Redmile Group's IMGN Position: Q1 2024 in Review
Redmile Group sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 16,423,922 shares — an estimated $487M sold.
Redmile Group first reported a position in IMGN in Q1 2017 and held it in 28 quarters. The position peaked at $487M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.
- Redmile Group reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
- Redmile Group sold 16,423,922 Immunogen Inc shares in Q1 2024, an estimated $487M.
- Redmile Group first reported a position in Immunogen Inc in Q1 2017 and held it in 28 quarters.
- Redmile Group's Immunogen Inc position peaked at $487M in Q4 2023.
- 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.
Based on Redmile Group's 13F filing for Q1 2024, filed 15 May 2024.